Funding news · Nov 13, 2026
Osmunda (奥咨达) Raises RMB 100M Series C+ to Build MAH Facility and AI Platform
Osmunda (奥咨达) Closes RMB 100M Series C+
Guangzhou-based medical-device services group Osmunda (奥咨达) has closed a RMB 100 million Series C+ round, according to funding data dated November 13, 2026. The round was solely invested by the Lishui Green Valley Talent Osmunda New Fund (丽水市绿谷人才奥咨达新基金).
Company Background
Osmunda was founded in 2004 by Dr. Zhang Feng and Pan Wei. The company describes itself as a pioneer of the medical-device CRO industry in China and operates what it calls the first one-stop comprehensive CXO platform for devices. That platform spans three service lines:
- CDO — research and development design
- CRO — clinical and regulatory registration
- CDMO — contract manufacturing
The company reports serving more than 5,000 device clients worldwide, including 70% of listed Chinese device makers, and says it has helped commercialize over 3,600 devices. Its model pairs shared production capacity with OSMED, a proprietary medical-device vertical large language model.
Use of Proceeds
The Series C+ proceeds are earmarked for two initiatives: building the company's headquarters MAH mass-production facility and developing an AI innovation platform. The MAH reference points to China's marketing authorization holder framework, under which the facility would support contract manufacturing tied to device registrations.
Deal Context
- Round type: Series C+
- Amount: RMB 100 million
- Date: November 13, 2026
- Sole investor: Lishui Green Valley Talent Osmunda New Fund
The round is notable for its single-investor structure, with the Lishui-linked fund providing the entire raise. For an acquisition-oriented read, the capital is directed at physical manufacturing capacity and AI tooling rather than at expanding the existing services footprint, suggesting Osmunda is deepening its CDMO and technology stack alongside its established CRO and CDO businesses.
What to Watch
The company's stated scale — thousands of device clients and commercialized devices — combined with a shared-production-capacity model gives it a broad base of device registrations and manufacturing relationships. The new MAH facility and OSMED AI platform are the two assets to track as the Series C+ capital is deployed.